21 completed, 4 recruiting, 2 not yet recruiting, 1 terminated. 28 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 21, Recruiting 4, Not yet recruiting 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss ponsegromab, placebo - Non-small Cell Lung Cancer (NSCLC), Cachexia | Phase 1 | Not yet recruiting | Pfizer | 80 | 2026-10-23 | 2026-09-25 |
| A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia GB18 - Cachexia; Cancer | Phase 1 | Recruiting | Kexing Biopharm Co., Ltd. | 18 | 2026-06-10 | 2026-06-12 |
| A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Nanocrystalline Megestrol Acetate Oral Suspension - Locally Advanced Cervical Cancer, Cachexia | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 88 | 2026-04-30 | 2026-04-24 |
| Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia DS010 injection - Cancer, Cachexia | Phase 1 / Phase 2 | Not yet recruiting | Dartsbio Pharmaceuticals Ltd. | 58 | 2026-04-30 | 2026-04-15 |
| A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia GFS202A injection - Cancer Cachexia | Phase 1 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 36 | 2025-04-24 | 2025-06-05 |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia AV-380 - Cachexia | Phase 1 | Recruiting | AVEO Pharmaceuticals, Inc. | 30 | 2023-06-13 | 2026-01-08 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects TCMCB07, Placebo - Cachexia | Phase 1 | Completed | Endevica Bio | 76 | 2022-07-12 | 2024-02-21 |
| Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV) Part 1 Group 1 Regime A (ACM-001.1), Part 1 Group 2 Regimen C (Pindolol), Part 2 Group D (Pindolol) - Cachexia | Phase 1 | Completed | Actimed Therapeutics Ltd | 51 | 2021-11-26 | 2023-10-10 |
| Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia PF-06946860, Placebo for PF-06946860 - Non-small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Completed | Pfizer | 18 | 2021-05-11 | 2024-01-12 |
| A Phase 1 Study of AV-380 in Healthy Subjects AV-380, Placebo - Cachexia | Phase 1 | Completed | AVEO Pharmaceuticals, Inc. | 51 | 2021-02-22 | 2023-06-12 |
| The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy Cannabidiol - Lean Body Mass, Cannabis | Phase 1 | Completed | University of Copenhagen | 32 | 2020-12-01 | 2023-07-24 |
| Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. PF-06946860 - Cachexia, Non-Small-Cell Lung Cancer | Phase 1 | Completed | Pfizer | 11 | 2020-11-17 | 2023-12-14 |
| Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia Remune, EXCAP©® - Cachexia; Cancer, Weight Loss | Phase 1 | Completed | University of Rochester | 25 | 2020-04-24 | 2023-08-15 |
| Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects NGM120, Placebo - Cachexia | Phase 1 | Completed | NGM Biopharmaceuticals, Inc | 92 | 2018-01-29 | 2019-08-20 |
| Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia Xilonix plus Onivyde and 5FU - Pancreatic Cancer, Cachexia | Phase 1 | Completed | Andrew Hendifar, MD | 16 | 2017-10-16 | 2020-12-30 |
| Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078 GSK2881078, Placebo, Itraconazole - Cachexia | Phase 1 | Completed | GlaxoSmithKline | 108 | 2015-09-01 | 2017-03-06 |
| A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate - Cachexia | Phase 1 | Completed | GlaxoSmithKline | 20 | 2014-05-05 | 2017-05-09 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses GSK2881078, Placebo - Cachexia | Phase 1 | Completed | GlaxoSmithKline | 99 | 2014-01-20 | 2018-07-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects GSK2849466, Placebo - Cachexia | Phase 1 | Completed | GlaxoSmithKline | 17 | 2012-09-26 | 2017-06-07 |
| Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers Megace F, Megace OS - Cachexia, Anorexia | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 103 | 2011-07-01 | 2012-07-02 |
Showing 20 of 28. Sign in to see all of them.
Cachexia (28) · Neoplasms (7) · Weight Loss (7) · Anorexia (4) · Carcinoma, Non-Small-Cell Lung (3) · Fatigue (3) · Pancreatic Neoplasms (3) · Colorectal Neoplasms (2) · HIV Infections (2) · Acquired Immunodeficiency Syndrome (1) · Adenocarcinoma (1) · Appetitive Behavior (1) · Body Weight Changes (1) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1)
Body Weight (28) · Pathological Conditions, Signs and Symptoms (28) · Signs and Symptoms (28) · Body Weight Changes (27) · Weight Loss (21) · Neoplasms by Site (7) · Signs and Symptoms, Digestive (6) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Genital Diseases (4) · Lung Diseases (4) · Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4)
GSK2881078 (2) · testosterone enanthate (2) · Adenosine Triphosphate (1) · Cannabidiol (1) · Dronabinol (1) · Exercise (1) · Fluorouracil (1) · Fluoxetine (1) · Ghrelin (1) · Itraconazole (1) · Megestrol Acetate (1) · Olanzapine (1) · Pentoxifylline (1) · Pindolol (1) · alkaloid GB18 (1)
GlaxoSmithKline (4) · Pfizer (4) · AVEO Pharmaceuticals, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Actimed Therapeutics Ltd (1) · Andrew Hendifar, MD (1) · Boryung Pharmaceutical Co., Ltd (1) · Cantonal Hospital of St. Gallen (1) · Dartmouth-Hitchcock Medical Center (1) · Dartsbio Pharmaceuticals Ltd. (1) · Endevica Bio (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Kexing Biopharm Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · NGM Biopharmaceuticals, Inc (1)
United States (19) · China (5) · Australia (1) · Canada (1) · Denmark (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Andrew Hendifar, MD (1) · Aung Naing, MD (1) · Crumpacker C (1) · Dezube B (1) · Egorin M (1) · Florian Strasser, PD Dr. MD (1) · Galetto G (1) · Jens Rikardt Andersen, MD (1) · Kyung-sang Yu, Dr. (1) · Li Zhang, MD (1) · Lionel D. Lewis, MD (1) · Maria Bermudez, MD, CPI (1) · Marion Couch, MD, PhD (1)
PMID 31391011, PMID 36056179, PMID 39665235
R01CA127971 (1)